Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
Table of Contents

The information contained in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to Completion
Preliminary Prospectus dated February 16, 2007
Common Stock
This is the initial public offering of our common stock. We are offering      shares of common stock.
We expect the initial public offering price to be between $      and $      per share. Currently, no public market exists for the shares of our common stock. After pricing of the offering, we expect that our common stock will be listed on the Nasdaq Global Market under the symbol “OREX.”
Investing in our common stock involves risks that are described in the “Risk Factors” section beginning on page 9 of this prospectus.
    Per Share   Total
Public offering price
  $   $
Underwriting discount
  $   $
Proceeds, before expenses, to us
  $   $
The underwriters may also purchase up to an additional      shares of common stock from us at the public offering price, less the underwriting discount, within 30 days from the date of this prospectus to cover overallotments.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The shares of common stock will be ready for delivery on or about           , 2007.
Merrill Lynch & Co.
JMP Securities
  Leerink Swann & Company
The date of this prospectus is          , 2007.